Expired activity
Please go to the PowerPak homepage and select a course.

Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology: Evolving Evidence Base, Current Value Assessment Frameworks, and Considerations for Decision Making in Managed Care Settings

This CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This educational activity is supported by independent medical education grants from AstraZeneca, GlaxoSmithKline, and Merck & Co., Inc.

Activity Description

PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the potential of PARP inhibitors in cancer care include application of recommended testing strategies to guide patient selection, individualized treatment planning, and management of treatment-related toxicities.

In this PeerView activity, oncology and pharmacy experts will review the latest evidence on the use of PARP inhibitors in the treatment of different tumors, including breast, ovarian, pancreatic, and prostate cancers, as well as oncology value assessment frameworks and strategies for assessing the benefits, risks, and costs to guide decisions regarding the use of this class of agents. Additionally, practical guidance will be provided for optimizing outcomes for cancer patients who may benefit from PARP inhibitor therapy in managed care settings.

Target Audience

This activity has been designed to meet the educational needs of oncologists, managed care pharmacists, medical directors, payer physicians, nurse case managers, oncology nurses and other clinicians involved in the management of care.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including ovarian, breast, pancreatic, prostate, and other malignancies
  • Assess the PARP inhibitors in terms of their mechanisms of action, efficacy and safety profiles, requirements for predictive testing to guide patient selection, nuances of administration and use, and other factors relevant to their value assessment in managed care settings
  • Implement appropriate decisions regarding the integration and use of PARP inhibitors in cancer care in managed care settings based on balanced assessments of all the evidence and unique characteristics of this class of agents

Continuing Pharmacy Education

acpeThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-0000-21-040-H01-P
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.

Release Date

November 6, 2020

Expiration Date

December 6, 2021

Faculty Disclosures

Co-Chair & Presenter
Kathleen N. Moore, MD, MS
Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics
Associate Director Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen, Inc.; Aravive; AstraZeneca; Eisai Co., Ltd; Elevar Therapeutics; GlaxoSmithKline/Tesaro; ImmunoGen Inc.; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics; and VBL Therapeutics.

Co-Chair & Presenter
Kristi Jhangiani, PharmD, BCPS
Clinical Program Development Manager
MedImpact Healthcare Systems
San Diego, California

Kristi Jhangiani, PharmD, BCPS, has no financial interests/relationships or affiliations in relation
to this activity.

Planning Committee Disclosures
Tracy L. Greene, MSN, RN, FNP-C, Nurse Planner, MLI, has nothing to disclose.
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures
The following Content/Peer Reviewers have nothing to disclose:

Kaushal Patel, MD
Bobbie Perrin, MSN, APRN, FNP-C        
Patricia A. Ensor, RPh, MBA

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

During the period November 6, 2020 to November 5, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  Your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

About This CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.